Pharmaceuticals News and Research

RSS

Genzyme ranked third on the global list for best employers

Genzyme Corporation announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

15 Oct 2009

PIKAMAB obtains U.S. patent rights to develop theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.

15 Oct 2009

Resveratrol in red grapes offers some protection against diabetes

A naturally produced molecule called resveratrol, found in the skin of red grapes, has been shown to lower insulin levels in mice when injected directly into the brain, even when the animals ate a high-fat diet.

15 Oct 2009

Health Sciences South Carolina, Recombinant Data and Sun Microsystems to collaborate on an Integrated Platform for Research

Health Sciences South Carolina (HSSC), today announced that it has selected Recombinant Data Corp. and Sun Microsystems, Inc. to collaborate on the Health Sciences South Carolina Integrated Platform for Research (HS-SCIPR), an unprecedented statewide initiative for translational research and quality improvement.

15 Oct 2009

Co-promotion agreement to promote Prosed DS to urologists and retail pharmacists

Timm Medical Technologies, Inc., a specialist Urology company, announced today its exclusive co-promotion agreement with Ferring Pharmaceuticals Inc., a Swiss-based biopharmaceutical company, for Prosed® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate) in the United States.

15 Oct 2009

Envoy Therapeutics raises $8 million through private placement

Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced the closing of its first financing, an $8 million private placement of the company’s Series A Preferred Stock. Led by 5AM Ventures, other investors participating in the financing included Takeda Research Investment and Roche Venture Fund.

15 Oct 2009

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

Paratek Pharmaceuticals, Novartis ink worldwide licensing agreement for PTK 0796

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented its client, Paratek Pharmaceuticals, Inc. in a worldwide licensing agreement with Novartis for its late-stage antibiotic, PTK 0796.

15 Oct 2009

Evonik Industries to acquire Tippecanoe Laboratories from Eli Lilly

Eli Lilly and Company today announced the sale of its Tippecanoe Laboratories manufacturing facility to Evonik Industries AG, one of the world's largest chemical companies.

15 Oct 2009

La Jolla Pharmaceutical announces a special shareholder meeting to seek approval of dissolution

La Jolla Pharmaceutical Company today announced that it has called a special meeting of stockholders for October 30, 2009 for the purpose of voting on a Plan of Complete Liquidation and Dissolution.

15 Oct 2009

Mylan Pharmaceuticals and Matrix Laboratories enter into license agreement with Pfizer

Mylan Inc. today announced that the company's Mylan Pharmaceuticals and Matrix Laboratories subsidiaries entered into a settlement and license agreement with Pfizer Inc. relating to Voriconazole Tablets, 50 mg and 200 mg, the generic version of Pfizer's Vfend Tablets, a triazole antifungal agent.

15 Oct 2009

Decision Resources forecasts biosimilar insulins and insulin analogues to erode $6.1 billion in brand sales

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilar insulins and insulin analogues stand to erode $6.1 billion in brand sales in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018, saving healthcare systems $3.8 billion in the process.

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

PharmaTelevision teams up with EBD Group to offer Television Interview and Media Training

PharmaTelevision(R), the authoritative channel for the pharmaceutical, biotechnology and related industries, today announced that it is teaming up with the EBD Group to offer delegates at BIO-Europe a Television Interview and Media Training.

15 Oct 2009

Critical Pharmaceuticals to develop hGH nasal spray

Critical Pharmaceuticals, the speciality pharmaceuticals company, today announced that it had secured a £1.5m translation award from the Wellcome Trust to develop a nasal spray of Human Growth Hormone (hGH) using its proprietary CriticalSorb technology as an alternative to injection.

15 Oct 2009

IQPC to hold the 8th Annual Polymorphism & Crystallization Scientific Forum

Organized by IQPC, the 8th Annual Polymorphism & Crystallization Scientific Forum will be held October 26-28, 2009 at the Hub Cira Center in Philadelphia, PA (www.polymorphismforum.com).

From IQPC Ltd 15 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

Commonwealth Biotechnologies to acquire GL Biochem

Commonwealth Biotechnologies, Inc. has recently announced a definitive share purchase agreement to acquire Shanghai-based GL Biochem and associated businesses (the “GL Group”), the largest global supplier of research-grade peptide products and peptide reagents.

15 Oct 2009

Lexicon Pharmaceuticals completes public offering of common stock shares

Lexicon Pharmaceuticals, Inc. today announced the completion of its previously-announced public offering of shares of its common stock. The offering included an aggregate of 38,333,332 shares of Lexicon's common stock after the exercise in full by the underwriters of their over-allotment option and by Invus, L.P., Lexicon's largest stockholder, of its associated right to purchase additional shares.

15 Oct 2009

Eden Biodesign to manufacture Biotecnol's Cardiotrophin-1

Eden Biodesign, a globally-integrated provider of biopharmaceutical process development, cGMP manufacturing and consultancy services, today announced it has been selected by Biotecnol SA to manufacture Cardiotrophin-1 for potential use in certain liver indications.

15 Oct 2009

Pharmaceuticals News and Research

Genzyme ranked third on the global list for best employers

PIKAMAB obtains U.S. patent rights to develop theragnostic product

Resveratrol in red grapes offers some protection against diabetes

Health Sciences South Carolina, Recombinant Data and Sun Microsystems to collaborate on an Integrated Platform for Research

Co-promotion agreement to promote Prosed DS to urologists and retail pharmacists

Envoy Therapeutics raises $8 million through private placement

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

Paratek Pharmaceuticals, Novartis ink worldwide licensing agreement for PTK 0796

Evonik Industries to acquire Tippecanoe Laboratories from Eli Lilly

La Jolla Pharmaceutical announces a special shareholder meeting to seek approval of dissolution

Mylan Pharmaceuticals and Matrix Laboratories enter into license agreement with Pfizer

Decision Resources forecasts biosimilar insulins and insulin analogues to erode $6.1 billion in brand sales

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

PharmaTelevision teams up with EBD Group to offer Television Interview and Media Training

Critical Pharmaceuticals to develop hGH nasal spray

IQPC to hold the 8th Annual Polymorphism & Crystallization Scientific Forum

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Commonwealth Biotechnologies to acquire GL Biochem

Lexicon Pharmaceuticals completes public offering of common stock shares

Eden Biodesign to manufacture Biotecnol's Cardiotrophin-1

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring